Sign inJoin waitlistJoin the waitlist

Isabella Glitza

Deputy Division Head, Department of Melanoma Medical Oncology, Division of Cancer Medicine · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

Department of Melanoma Medical Oncology Division · University of Texas M D Anderson Cancer Center
Present
Division of Cancer Medicine · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
2025–Present

UT Health Graduate School of Biomedical Sciences
2016
Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2007–2010
Internal Medicine
Jefferson Health Medical Education
2004–2007
Ruprecht Karl University of Heidelberg
2005
Doctor of Medicine
2000–2004

Research

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Science · 2018 · 3,866 citations
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Cancer Discovery · 2016 · 1,305 citations
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Cancer Discovery · 2016 · 809 citations

Michael Davies
34 papers
AD
Adi Diab
27 papers
Hussein Tawbi
26 papers
Sapna Patel
25 papers
Rodabe Amaria
24 papers
Patrick Hwu
23 papers
Michael Tetzlaff
21 papers
Jennifer Wargo
20 papers
Jeffrey Gershenwald
17 papers
Scott Woodman
16 papers
Jennifer McQuade
15 papers · 4 as a fellow
Alexander Lazar
13 papers · 3 as a fellow

Grants

The University of Texas MD Anderson Cancer Center SPORE in Melanoma
National Cancer Institute · P50
Project lead · $991.5K · University of Tx Md Anderson Can Ctr
2019–2026

Clinical trials

Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma
Principal investigator · Not yet recruiting · Phase 1
M.D. Anderson Cancer Center
2026–2030
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2021–2027
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2019–2025
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
Principal investigator · Active not recruiting · Phase 1
M.D. Anderson Cancer Center
2018–2027